StockNow
Calendar
Log in
Global Markets

Novo Nordisk (NOVOB DC) to present new liver data across Wegovy 2.4mg and investigational efruxifermin at The Liver Meeting 2026

ORIGINAL · NewsquawkNovo Nordisk (NOVOB DC) to present new liver data across Wegovy 2.4mg and investigational efruxifermin at The Liver Meeting 2026
StockNow breaking-news AI analysis

Novo announced 12 scheduled abstracts on semaglutide and efruxifermin at The Liver Meeting 2026; the retrieved announcement provides study descriptions and presentation times, but no numerical findings.

1 stocks
NVONovo-Nordisk A/S$38.48Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Politics

Reports of a Yemeni attack targeting Saudi forces in Aden, Sabereen reports

Geopolitics

Ukrainian President Zelensky says negotiations between Ukraine, Russia and the US could take place as early as November 10th

U.S. Markets

Phillips 66 (PSX) Q3 2026 (USD): Adj. EPS 14.08 (exp. 11.73)

PSX